IRIS
IAFFALDANO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.230
AS - Asia 2.056
EU - Europa 1.671
SA - Sud America 495
AF - Africa 165
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.632
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.138
SG - Singapore 854
CN - Cina 505
BR - Brasile 418
SE - Svezia 350
IT - Italia 317
RU - Federazione Russa 314
HK - Hong Kong 301
GB - Regno Unito 177
VN - Vietnam 153
DE - Germania 141
CI - Costa d'Avorio 113
FI - Finlandia 71
FR - Francia 70
CA - Canada 54
NL - Olanda 44
JP - Giappone 43
AR - Argentina 41
IN - India 40
UA - Ucraina 38
BE - Belgio 32
ID - Indonesia 29
BD - Bangladesh 27
MX - Messico 24
PL - Polonia 24
AT - Austria 21
SA - Arabia Saudita 18
ZA - Sudafrica 18
IQ - Iraq 16
ES - Italia 12
TR - Turchia 11
LT - Lituania 10
CO - Colombia 8
CZ - Repubblica Ceca 8
EC - Ecuador 8
IL - Israele 8
AU - Australia 7
UZ - Uzbekistan 7
EG - Egitto 6
IE - Irlanda 6
IR - Iran 6
KE - Kenya 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
PK - Pakistan 5
PT - Portogallo 5
RO - Romania 5
TN - Tunisia 5
EE - Estonia 4
UY - Uruguay 4
AL - Albania 3
BB - Barbados 3
CH - Svizzera 3
DK - Danimarca 3
EU - Europa 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
LV - Lettonia 3
MA - Marocco 3
NP - Nepal 3
PA - Panama 3
PY - Paraguay 3
A1 - Anonimo 2
AZ - Azerbaigian 2
BG - Bulgaria 2
DZ - Algeria 2
ET - Etiopia 2
HU - Ungheria 2
JM - Giamaica 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PH - Filippine 2
RW - Ruanda 2
SN - Senegal 2
BF - Burkina Faso 1
BJ - Benin 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GL - Groenlandia 1
GR - Grecia 1
HN - Honduras 1
HT - Haiti 1
IS - Islanda 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MR - Mauritania 1
MW - Malawi 1
NG - Nigeria 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
Totale 9.628
Salva come PNG Salva come JPEG
Città #
Ashburn 616
Fairfield 616
Chandler 431
Singapore 402
Woodbridge 378
Dallas 310
Hong Kong 301
Houston 271
Nyköping 270
Seattle 254
Ann Arbor 240
Cambridge 211
Wilmington 175
Beijing 174
Abidjan 113
Los Angeles 92
Lawrence 80
Jacksonville 77
New York 75
Roxbury 71
Bari 66
Brooklyn 55
Ho Chi Minh City 55
Des Moines 48
São Paulo 47
Boardman 46
Munich 41
Nanjing 41
Tokyo 39
Buffalo 38
Chicago 37
Princeton 37
London 35
Moscow 34
Santa Clara 34
Brussels 32
Helsinki 31
Inglewood 30
Nuremberg 30
San Diego 27
Amsterdam 26
Frankfurt am Main 26
Guangzhou 26
North Bergen 26
Toronto 25
Hanoi 22
Paris 20
Jakarta 19
Norwalk 19
Orem 19
Salt Lake City 18
Shanghai 16
Warsaw 16
Poplar 15
Rio de Janeiro 15
Atlanta 14
Montreal 14
Dong Ket 13
Johannesburg 13
Tianjin 13
Milan 12
Rome 12
Stockholm 12
Bisceglie 11
San Francisco 11
Shenyang 11
Nanchang 10
Dearborn 9
Denver 9
Dhaka 9
Jeddah 9
Manchester 9
Phoenix 9
Taranto 9
Vienna 9
Washington 9
Boston 8
Cagliari 8
Chennai 8
Haiphong 8
San Jose 8
Wuhan 8
Belo Horizonte 7
Falkenstein 7
Hebei 7
Jiaxing 7
Mexico City 7
Mumbai 7
Ankara 6
Brno 6
Columbus 6
Da Nang 6
Dublin 6
Elk Grove Village 6
Falls Church 6
Jackson 6
Kilburn 6
Porto Alegre 6
The Dalles 6
Cairo 5
Totale 6.656
Salva come PNG Salva come JPEG
Nome #
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 199
Signs and symptoms of COVID-19 in patients with multiple sclerosis 184
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 172
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 172
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 170
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 162
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 161
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial 160
Prognostic indicators in pediatric clinically isolated syndrome 159
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 156
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 149
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 146
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 143
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 143
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 140
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 137
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 133
Multiple sclerosis registries in Europe – An updated mapping survey 132
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 131
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 127
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 124
Treatment decisions in multiple sclerosis-insights from real-world observational studies 122
Treating multiple sclerosis with natalizumab. 119
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 116
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 110
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 110
null 109
Emotional and neutral verbal memory impairment in Multiple Sclerosis 109
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 108
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 107
Sclerosi Multipla e Lavoro: dati preliminari 106
Safety profile of Tysabri: international risk management plan 105
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 105
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 105
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 104
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients 104
Low serum urate levels are associated to female gender in multiple sclerosis patients. 103
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis 102
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 101
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 101
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 100
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study 100
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 98
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 98
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 97
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 96
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 95
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 94
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients 92
Predictors and dynamics of postpartum relapses in women with multiple sclerosis. 91
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 91
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 91
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 90
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 90
Multiple Sclerosis Progression and Relapse Activity in Children 89
Geographical variations in sex ratio trends over time in multiple sclerosis. 83
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis 83
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 82
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 82
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 82
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 81
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 80
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 80
Disability assessment using Google Maps 77
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 75
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 74
Natalizumab reduces serum pro-angiogenic activity in MS patients 74
A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis 74
null 73
Assessing long-term effectiveness of MS treatment - a matter of debate 69
null 68
Anxiety state affects information processing speed in patients with multiple sclerosis 68
null 67
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study 67
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 66
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis 66
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 65
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 65
null 65
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 62
Big Multiple Sclerosis Data network: an international registry research network 62
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 57
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 57
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network 57
null 56
null 55
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 55
Risk of Getting COVID-19 in People With Multiple Sclerosis 54
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 52
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 52
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 51
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 51
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 50
Serum N-acetyl aspartate (NAA) levels differ in multiple sclerosis (MS) and neuromyelitis optica (NMO). 49
Real-life impact of early interferonbeta therapy in relapsing multiple sclerosis 49
Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate 48
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 48
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 48
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 45
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 42
Totale 9.524
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.159
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.159
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021569 0 0 0 0 0 83 68 75 64 109 90 80
2021/2022754 61 72 21 23 49 87 34 44 51 48 117 147
2022/20231.102 158 170 88 87 128 131 20 120 151 4 26 19
2023/2024442 41 54 29 24 41 95 16 25 6 30 11 70
2024/20252.094 149 38 126 74 68 153 223 187 126 116 291 543
2025/20262.826 653 362 478 473 540 320 0 0 0 0 0 0
Totale 10.066